Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: A naturalistic study
Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: A naturalistic study
复制标题
DOI：
10.1097/dbp.0b013e318165c100
复制
发表时间：
2008-04-01
影响因子：
2.4
通讯作者：
Kammann, Heather
中科院分区：
文献类型：
--
作者：
Capone, George T.;Goyal, Parag;Kammann, Heather
目的：我们报告了一项使用利培酮治疗唐氏综合征、严重智力残疾和共病自闭症谱系障碍（DS+ ASD）儿童的破坏性行为和自伤的开放标签、自然主义研究。我们假设，多动和破坏性行为将改善利培酮治疗与先前的研究与儿童ASD一致。研究方法：受试者为儿童（平均年龄7.8 ± 2.6岁），包括2000年至2004年期间通过我们的唐氏综合征门诊确定的20名男性和3名女性。结果如下：使用异常行为检查表作为主要的结果测量，所有五个分量表显示利培酮治疗后显着改善。平均治疗持续时间为95.8 ± 16.8天，平均总日剂量为0.66 ± 0.28 mg/天。多动、刻板和嗜睡子量表评分显示出最显著的降低（p
Objective: We report on an open-label, naturalistic study using risperidone to treat disruptive behaviors and self-injury in children with Down syndrome, severe intellectual disability, and comorbid autism spectrum disorders (DS+ASDs). We hypothesized that hyperactivity and disruptive behaviors would improve in response to risperidone treatment consistent with previous studies of children with ASD. Methods: Subjects were children (mean age, 7.8 +/- 2.6 years), consisting of 20 males and three females identified through our outpatient Down Syndrome Clinic between 2000 and 2004. Results: Using the Aberrant Behavior Checklist as the primary outcome measure, all five subscales showed significant improvement following risperidone treatment. The mean duration of treatment was 95.8 +/- 16.8 days, and mean total daily dose was 0.66 +/- 0.28 mg/day. The Hyperactivity, Stereotypy, and Lethargy subscale scores showed the most significant reduction (p